Laura Marandino (@lauramarandino) 's Twitter Profile
Laura Marandino

@lauramarandino

Clinical Research Fellow in Renal & Melanoma @royalmarsdenNHS/ Member @EAUYAU_RenalCa

ID: 3165973965

calendar_today14-04-2015 13:01:35

494 Tweet

689 Followers

986 Following

James Brugarolas (@jbrugarolas) 's Twitter Profile Photo

Congratulations to the team including Nizar MD Anderson Cancer Center Brian Rini, MD on first #siRNA #RCC phase 1 bit.ly/AROHIF2trial with ArrowheadPharma #HIF2 siRNA building upon bit.ly/siHIF2RCCpre (PMID36190432) opening new field.

Congratulations to the team including Nizar <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/brian_rini/">Brian Rini, MD</a> on first #siRNA #RCC phase 1 bit.ly/AROHIF2trial with <a href="/ArrowheadPharma/">ArrowheadPharma</a> #HIF2 siRNA building upon bit.ly/siHIF2RCCpre (PMID36190432) opening new field.
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Fantastic meeting of IMG Oncologists (37% of practicing oncologists in USA) steered by Toni Choueiri, MD Ziad Bakouny, MD, MSc Nazli Dizman 👉Challenges faced by IMGs, Insights from the 2023 meeting, how to join the group👇ASCO #ASCO24 #IMGCoP meeting overview 👇OncoAlert #ASCODailyNews

Fantastic meeting of <a href="/IMG_Oncologists/">IMG Oncologists</a> (37% of practicing oncologists in USA) steered by <a href="/DrChoueiri/">Toni Choueiri, MD</a> <a href="/ZiadBakouny/">Ziad Bakouny, MD, MSc</a> <a href="/NazliDizman/">Nazli Dizman</a> 👉Challenges faced by IMGs, Insights from the 2023 meeting, how to join the group👇<a href="/ASCO/">ASCO</a> #ASCO24 #IMGCoP meeting overview 👇<a href="/OncoAlert/">OncoAlert</a> #ASCODailyNews
The Crick (@thecrick) 's Twitter Profile Photo

We're delighted to lead a new project with @RoyalMarsdenNHS to study responses to cancer immunotherapy. The platform has received £20m+ in public and industry investment and will involve thousands of people from across the UK receiving immunotherapy. 🔗 crick.ac.uk/news-and-repor…

Turajlic Lab @ The Crick (@turajliclab) 's Twitter Profile Photo

Delighted to announce the launch of our MANIFEST IO research platform MANIFEST IO. 🔬 We are a UK-wide consortium of academic institutions, NHS trusts & industry partners - with a shared vision to understand how patients with cancer can best benefit from immunotherapy. 🧵1/5

Delighted to announce the launch of our MANIFEST IO research platform <a href="/MANIFEST_CIRRP/">MANIFEST IO</a>.

🔬 We are a UK-wide consortium of academic institutions, NHS trusts &amp; industry partners - with a shared vision to understand how patients with cancer can best benefit from immunotherapy. 🧵1/5
Gaëlle Margue (@gaellemargue) 's Twitter Profile Photo

Engaging rapid-fire debate on kidney cancer management at #EMUC2024! Experts tackled challenges in surgery, systemic therapies, and the role of SBRT. Great insights into the future of personalized care. #KidneyCancer #UroOncology EAU-YAU Renal Cancer Working Group European Association of Urology (EAU)

Engaging rapid-fire debate on kidney cancer management at #EMUC2024! Experts tackled challenges in surgery, systemic therapies, and the role of SBRT. Great insights into the future of personalized care. #KidneyCancer #UroOncology <a href="/EAUYAU_RenalCa/">EAU-YAU Renal Cancer Working Group</a> <a href="/Uroweb/">European Association of Urology (EAU)</a>
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

📢 Join the Florence Multidisciplinary Expert Meeting on Renal Cell Carcinoma! 🗓 Dates: January 17-18, 2025 📍 Venue: Grand Hotel Mediterraneo, Florence Can’t attend in person? Follow the event online for free: ✅ Day 1: attendee.gotowebinar.com/register/87062… ✅ Day 2: attendee.gotowebinar.com/register/76662…

📢 Join the Florence Multidisciplinary Expert Meeting on Renal Cell Carcinoma!
🗓 Dates: January 17-18, 2025
📍 Venue: Grand Hotel Mediterraneo, Florence

Can’t attend in person? Follow the event online for free:
✅ Day 1: attendee.gotowebinar.com/register/87062…
✅ Day 2: attendee.gotowebinar.com/register/76662…
Srinivas Viswanathan (@srviswanathan) 's Twitter Profile Photo

🚨 New study! 🚨Excited to share our research on #translocationRCC #tRCC published in Nature Metabolism, in collaboration with @lironbarpeled. We reveal how the TFE3 fusion drives a key oxidative phosphorylation (OXPHOS) metabolic program in this kidney cancer. 1/ Dana-Farber News

🚨 New study! 🚨Excited to share our research on #translocationRCC #tRCC published in <a href="/NatMetabolism/">Nature Metabolism</a>, in collaboration with @lironbarpeled. We reveal how the TFE3 fusion drives a key oxidative phosphorylation (OXPHOS) metabolic program in this kidney cancer. 1/ <a href="/DanaFarberNews/">Dana-Farber News</a>
Pavlos Msaouel (@pavlosmsaouel) 's Twitter Profile Photo

1/5 Sharing our Clinical Cancer Research work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/… The V Foundation for Cancer Research Chris Johnson Foundation Inc.

1/5 Sharing our <a href="/CCR_AACR/">Clinical Cancer Research</a> work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/… <a href="/TheVFoundation/">The V Foundation for Cancer Research</a> <a href="/renalmedullary/">Chris Johnson Foundation Inc.</a>
Max Emmerich (@maxemmerichderm) 's Twitter Profile Photo

Delighted to present our Turajlic Lab @ The Crick work on utilising AI-assisted high dimensional PBMC profiling to predict IO response and toxicity as a late breaking poster and talk at #AACRIO2025 today. Great collaboration with our partners at #IMUBiosciences as part of MANIFEST IO

Delighted to present our <a href="/TurajlicLab/">Turajlic Lab @ The Crick</a> work on utilising AI-assisted high dimensional PBMC profiling to predict IO response and toxicity as a late breaking poster and talk at #AACRIO2025 today. 
Great collaboration with our partners at #IMUBiosciences as part of <a href="/MANIFEST_CIRRP/">MANIFEST IO</a>
EAU-YAU Renal Cancer Working Group (@eauyau_renalca) 's Twitter Profile Photo

Join Kidney Cancer Europe 2025: pre-conference surgical workshop Cutting-Edge on kidney focused on local therapies for advanced RCC YAU RCC will be there contributing to the conversation 🗓️ May 1, 2025 – Amsterdam 📍 Register at kidneycancer.org

Join <a href="/KidneyCancer/">Kidney Cancer</a> Europe 2025: pre-conference surgical workshop Cutting-Edge on kidney focused on local therapies for advanced RCC 

YAU RCC will be there contributing to the conversation

🗓️ May 1, 2025 – Amsterdam
📍 Register at kidneycancer.org
Sarah Scagliarini, MD (@sscagliarini_) 's Twitter Profile Photo

🧬 Thanks to Margaret Ottaviano for the invitation to “Second Mediterranean Conference: Embracing Cancer Immunotherapy” 💉Stay hungry, don't stop learning, be inspired by the energy of research, don't stop dreaming that we can do even more! Congrats to all! OncoDaily IO OncoAlert

🧬 Thanks to <a href="/MargaretOttavi1/">Margaret Ottaviano</a> for the invitation to “Second Mediterranean Conference: Embracing Cancer Immunotherapy” 💉Stay hungry, don't stop learning, be inspired by the energy of research, don't stop dreaming that we can do even more! Congrats to all! <a href="/OncoDailyIO/">OncoDaily IO</a> <a href="/OncoAlert/">OncoAlert</a>
Daniele Raggi (@danieleraggi83) 's Twitter Profile Photo

Excited to share our new review on the Management of Testicular Cancer just out in JCO Oncology Practice ! A practical overview on diagnosis, treatment, and survivorship. Robert Huddart💙 Alison Reid Walter Cazzaniga Deep Chakrabarti OncoAlert Check it out here: ascopubs.org/doi/10.1200/OP…

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

📢 #ASCO25 | NEOAVAX Ph II | High‐risk localized RCC: Neoadjuvant avelumab + axitinib × 12 wks pre‐nephrectomy in 40 pts: 30% ORR (12/40 PR), 20% median tumor downsizing; among responders, 10/12 were disease‐free at 23.5 mo median FU; no primary tumor progression.

📢 #ASCO25 | NEOAVAX Ph II | High‐risk localized RCC: Neoadjuvant avelumab + axitinib × 12 wks pre‐nephrectomy in 40 pts: 30% ORR (12/40 PR), 20% median tumor downsizing; among responders, 10/12 were disease‐free at 23.5 mo median FU; no primary tumor progression.